Heart Test Laboratories, Inc., also known as HeartSciences, has successfully regained compliance with the Nasdaq's minimum bid price requirement, as confirmed by a letter from The Nasdaq Stock Market LLC received on June 3, 2024. The company's common stock had previously failed to meet the $1.00 minimum closing bid price for 30 consecutive business days, leading to non-compliance notification from Nasdaq on August 2, 2023. To rectify this, HeartSciences was required to maintain a closing bid price of at least $1.00 for 10 consecutive trading days, a condition it fulfilled by May 31, 2024. As a result, the scheduled appeal hearing on June 27, 2024, has been canceled, and the company's common stock and warrants will continue to be listed on the Nasdaq. HeartSciences, a medical technology company leveraging AI to enhance ECGs for early heart disease detection, announced the compliance achievement in a press release on June 4, 2024. The company is developing AI-ECG solutions and is working towards FDA clearance for its MyoVista® wavECG™ device.

Heart Test Laboratories, Inc., also known as HeartSciences, has successfully regained compliance with the Nasdaq's minimum bid price requirement, as confirmed by a letter from The Nasdaq Stock Market LLC received on June 3, 2024. The company's common stock had previously failed to meet the $1.00 minimum closing bid price for 30 consecutive business days, leading to non-compliance notification from Nasdaq on August 2, 2023. To rectify this, HeartSciences was required to maintain a closing bid price of at least $1.00 for 10 consecutive trading days, a condition it fulfilled by May 31, 2024. As a result, the scheduled appeal hearing on June 27, 2024, has been canceled, and the company's common stock and warrants will continue to be listed on the Nasdaq. HeartSciences, a medical technology company leveraging AI to enhance ECGs for early heart disease detection, announced the compliance achievement in a press release on June 4, 2024. The company is developing AI-ECG solutions and is working towards FDA clearance for its MyoVista® wavECG™ device.